Canagliflozin plus gemcitabine for pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial studies whether adding canagliflozin to standard chemotherapy (gemcitabine) can slow pancreatic cancer that cannot be fully removed by surgery. It may help some people control the cancer for longer and improve how well treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have confirmed pancreatic cancer that is metastatic or cannot be surgically removed
- Your estimated survival is more than 3 months
- You have not had chemotherapy recently (either none yet, or at least 1 month since your last course ended)
- Your overall ability to do daily activities is fairly good (ECOG score 0 to 2)
- You can take medicines by mouth
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a diabetes treatment to standard chemotherapy helps people with pancreatic cancer that has spread and who also have diabetes. It might improve how well the cancer is controlled and how you feel.
This trial tests whether adding a traditional Chinese herb (Astragalus) to a standard chemotherapy drug (gemcitabine) before surgery works better than gemcitabine alone for treating pancreatic cancer. People who can join will have locally advanced or borderline resectable cancer that hasn't spread to distant organs.
This study tests whether adding pitavastatin (a cholesterol-lowering drug) to gemcitabine chemotherapy can help treat pancreatic cancer that cannot be surgically removed. You would join if your cancer hasn't grown worse after 2–4 rounds of gemcitabine.
This trial studies a chemotherapy combination (albumin-bound paclitaxel and gemcitabine) as first treatment for pancreatic cancer that cannot be removed by surgery. It aims to improve outcomes by testing how well this treatment works in people with locally advanced or metastatic disease.
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
This trial tests a new drug, LM-302, combined with gemcitabine for people with a specific type of advanced pancreatic cancer that has not responded to or stopped working on first-line treatment. The goal is to see if the combination is safe and effective.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.